12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Eli Lilly, NIH deal

Eli Lilly and NIH partnered to generate publicly available biological profiles for approved and investigational medicines. The partners will use Lilly's Phenotypic Drug Discovery panel (PD2) to screen 3,800 compounds in NIH's National Center for Advancing Translational Sciences (NCATS) Pharmaceutical Collection over the next 12-18 months. Results will be freely available online. The partners...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >